company background image
6004

Zhangzhou Pientzehuang Pharmaceutical SHSE:600436 Stock Report

Last Price

CN¥252.69

Market Cap

CN¥152.5b

7D

-13.8%

1Y

-25.6%

Updated

25 Sep, 2022

Data

Company Financials +
600436 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance6/6
Financial Health6/6
Dividends4/6

600436 Stock Overview

Zhangzhou Pientzehuang Pharmaceutical., Ltd engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally.

Zhangzhou Pientzehuang Pharmaceutical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zhangzhou Pientzehuang Pharmaceutical
Historical stock prices
Current Share PriceCN¥252.69
52 Week HighCN¥486.15
52 Week LowCN¥250.22
Beta0.86
1 Month Change-14.05%
3 Month Change-28.42%
1 Year Change-25.60%
3 Year Change149.89%
5 Year Change333.73%
Change since IPO7,502.35%

Recent News & Updates

Shareholder Returns

600436CN PharmaceuticalsCN Market
7D-13.8%-4.6%-1.9%
1Y-25.6%-24.5%-18.6%

Return vs Industry: 600436 underperformed the CN Pharmaceuticals industry which returned -24.5% over the past year.

Return vs Market: 600436 underperformed the CN Market which returned -18.6% over the past year.

Price Volatility

Is 600436's price volatile compared to industry and market?
600436 volatility
600436 Average Weekly Movement3.5%
Pharmaceuticals Industry Average Movement4.7%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.3%
10% least volatile stocks in CN Market3.7%

Stable Share Price: 600436 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 600436's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a2,591Jin Ming Huanghttps://www.zzpzh.com.cn

Zhangzhou Pientzehuang Pharmaceutical., Ltd engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally. The company’s products include medicines and health products, cosmetics, daily chemicals, medical apparatus and instruments, and health foods. The company is based in Zhangzhou, China.

Zhangzhou Pientzehuang Pharmaceutical Fundamentals Summary

How do Zhangzhou Pientzehuang Pharmaceutical's earnings and revenue compare to its market cap?
600436 fundamental statistics
Market CapCN¥152.45b
Earnings (TTM)CN¥2.63b
Revenue (TTM)CN¥8.60b

58.0x

P/E Ratio

17.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
600436 income statement (TTM)
RevenueCN¥8.60b
Cost of RevenueCN¥4.35b
Gross ProfitCN¥4.25b
Other ExpensesCN¥1.62b
EarningsCN¥2.63b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.36
Gross Margin49.41%
Net Profit Margin30.60%
Debt/Equity Ratio7.4%

How did 600436 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

28%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 600436 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600436?

Other financial metrics that can be useful for relative valuation.

600436 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue17.6x
Enterprise Value/EBITDA49.6x
PEG Ratio2.7x

Price to Earnings Ratio vs Peers

How does 600436's PE Ratio compare to its peers?

600436 PE Ratio vs Peers
The above table shows the PE ratio for 600436 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average31.8x
600276 Jiangsu Hengrui Medicine
52.7x19.5%CN¥210.0b
000538 Yunnan Baiyao GroupLtd
37.1x24.6%CN¥92.8b
600196 Shanghai Fosun Pharmaceutical (Group)
21.4x22.1%CN¥74.0b
000661 Changchun High-Tech Industries (Group)
15.9x24.1%CN¥62.9b
600436 Zhangzhou Pientzehuang Pharmaceutical
58x21.4%CN¥152.5b

Price-To-Earnings vs Peers: 600436 is expensive based on its Price-To-Earnings Ratio (58x) compared to the peer average (31.8x).


Price to Earnings Ratio vs Industry

How does 600436's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 600436 is expensive based on its Price-To-Earnings Ratio (58x) compared to the CN Pharmaceuticals industry average (29.4x)


Price to Earnings Ratio vs Fair Ratio

What is 600436's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600436 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio58x
Fair PE Ratio35.1x

Price-To-Earnings vs Fair Ratio: 600436 is expensive based on its Price-To-Earnings Ratio (58x) compared to the estimated Fair Price-To-Earnings Ratio (35.1x).


Share Price vs Fair Value

What is the Fair Price of 600436 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600436 (CN¥252.69) is trading below our estimate of fair value (CN¥319.38)

Significantly Below Fair Value: 600436 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Zhangzhou Pientzehuang Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


21.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600436's forecast earnings growth (21.4% per year) is above the savings rate (3.2%).

Earnings vs Market: 600436's earnings (21.4% per year) are forecast to grow slower than the CN market (25.8% per year).

High Growth Earnings: 600436's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 600436's revenue (16.5% per year) is forecast to grow slower than the CN market (18.2% per year).

High Growth Revenue: 600436's revenue (16.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 600436's Return on Equity is forecast to be high in 3 years time (24.2%)


Discover growth companies

Past Performance

How has Zhangzhou Pientzehuang Pharmaceutical performed over the past 5 years?

Past Performance Score

6/6

Past Performance Score 6/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


25.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 600436 has high quality earnings.

Growing Profit Margin: 600436's current net profit margins (30.6%) are higher than last year (27%).


Past Earnings Growth Analysis

Earnings Trend: 600436's earnings have grown significantly by 25.1% per year over the past 5 years.

Accelerating Growth: 600436's earnings growth over the past year (36.9%) exceeds its 5-year average (25.1% per year).

Earnings vs Industry: 600436 earnings growth over the past year (36.9%) exceeded the Pharmaceuticals industry 6%.


Return on Equity

High ROE: 600436's Return on Equity (25%) is considered high.


Discover strong past performing companies

Financial Health

How is Zhangzhou Pientzehuang Pharmaceutical's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 600436's short term assets (CN¥11.7B) exceed its short term liabilities (CN¥2.6B).

Long Term Liabilities: 600436's short term assets (CN¥11.7B) exceed its long term liabilities (CN¥213.1M).


Debt to Equity History and Analysis

Debt Level: 600436 has more cash than its total debt.

Reducing Debt: 600436's debt to equity ratio has reduced from 9.4% to 7.4% over the past 5 years.

Debt Coverage: 600436's debt is well covered by operating cash flow (698.1%).

Interest Coverage: 600436 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Zhangzhou Pientzehuang Pharmaceutical current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.48%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 600436's dividend (0.48%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.52%).

High Dividend: 600436's dividend (0.48%) is low compared to the top 25% of dividend payers in the CN market (2.1%).


Stability and Growth of Payments

Stable Dividend: 600436's dividends per share have been stable in the past 10 years.

Growing Dividend: 600436's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (27.8%), 600436's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (13.5%), 600436's dividend payments are thoroughly covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Jin Ming Huang (56 yo)

3.17yrs

Tenure

CN¥582,000

Compensation

Mr. Jin Ming Huang is GM & Director of Zhangzhou Pientzehuang Pharmaceutical., Ltd from July 2019. He joined the Zhangzhou Pientzehuang Pharmaceutical., Ltd in September 2006. Mr. Huang served as President...


Leadership Team

Experienced Management: 600436's management team is considered experienced (3.2 years average tenure).


Board Members

Experienced Board: 600436's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 62.25% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
54.54%
ZhangZhou JiuLongJiang Group Co., Ltd.
329,022,643CN¥83.1b-0.91%no data
4.48%
Fuji Wang
27,037,500CN¥6.8b0%no data
0.8%
Fujian Zhangzhou City Investment Group Company Limited
4,800,000CN¥1.2b0%no data
0.35%
E Fund Management Co., Ltd.
2,133,871CN¥539.2m0%0.13%
0.33%
BlackRock, Inc.
2,005,248CN¥506.7m0.33%no data
0.27%
The Vanguard Group, Inc.
1,630,826CN¥412.1m0%no data
0.23%
China Universal Asset Management Company Ltd.
1,400,051CN¥353.8m0%0.18%
0.18%
China Southern Asset Management Co., Ltd.
1,088,157CN¥275.0m-8.64%0.14%
0.17%
National Council for Social Security Fund
1,041,281CN¥263.1m0%0.05%
0.14%
Artisan Partners Limited Partnership
830,339CN¥209.8m-34.83%0.03%
0.12%
Hua An Fund Management Co., Ltd.
746,442CN¥188.6m0%0.14%
0.077%
William Blair Investment Management, LLC
461,700CN¥116.7m31.43%0.03%
0.075%
Harvest Fund Management Co., Ltd.
453,301CN¥114.5m-0.04%0.06%
0.07%
Norges Bank Investment Management
420,992CN¥106.4m0%no data
0.068%
Bosera Asset Management Co., Ltd.
411,712CN¥104.0m0%0.09%
0.051%
ABC-CA Fund Management Co., Ltd.
304,729CN¥77.0m0%0.2%
0.05%
Bank of Communications Schroder Fund Management Co., Ltd.
299,900CN¥75.8m0%0.08%
0.049%
Penghua Fund Management Co. Ltd.
294,938CN¥74.5m0%0.07%
0.042%
Krane Funds Advisors, LLC
255,129CN¥64.5m2.7%0.12%
0.032%
DBX Advisors LLC
190,059CN¥48.0m-36.34%0.06%
0.029%
Guotai Asset Management Co., Ltd.
174,829CN¥44.2m0%0.03%
0.026%
Broad Asset Management Co., Ltd
159,770CN¥40.4m0%0.28%
0.024%
Hwabao WP Fund Management Co., Ltd
147,326CN¥37.2m0%0.06%
0.022%
Invesco Great Wall Fund Management Co. Ltd
135,018CN¥34.1m0%0.02%
0.022%
AEGON-Industrial Fund Management Co., Ltd.
132,113CN¥33.4m0%0.02%

Company Information

Zhangzhou Pientzehuang Pharmaceutical., Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Zhangzhou Pientzehuang Pharmaceutical., Ltd
  • Ticker: 600436
  • Exchange: SHSE
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CN¥152.452b
  • Shares outstanding: 603.32m
  • Website: https://www.zzpzh.com.cn

Number of Employees


Location

  • Zhangzhou Pientzehuang Pharmaceutical., Ltd
  • Pien Tze Huang Building
  • 1st Floor
  • Zhangzhou
  • Fujian Province
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
600436SHSE (Shanghai Stock Exchange)YesDomestic SharesCNCNYJun 2003
600436XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect)YesDomestic SharesCNCNYJun 2003

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/25 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.